Paradigm Biopharma (ASX: PAR)

Currency in AUD

Last close As at 25/03/2023


0.02 (1.54%)

Market capitalisation


Paradigm Biopharmaceuticals is an Australian biotechnology company focused on the development of injectable pentosan polysulfate (iPPS). Its most advanced clinical programme is investigating the drug’s use as a potentially disease modifying treatment for knee osteoarthritis (kOA).

Knee osteoarthritis is a highly prevalent and quality-of-life impacting disease. Currently no disease modifying drugs are available for the condition, resulting in serious unmet medical needs and a potentially significant opportunity for drug developers.



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Simon White

    Director of investor relations

Balance Sheet

Forecast net debt (A$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (9.9) (12.6) 17.7
Relative (4.8) (10.7) 24.5
52 week high/low A$2.1/A$0.9


Paradigm has presented its half yearly results and accounts, reflecting an active period. This included an encouraging safety review for injectable pentosan polysulfate sodium (iPPS, Zilosul) in the pivotal Phase III trial (PARA_OA_002) for patients with knee osteoarthritis (kOA) pain. The Phase II (PARA_OA_008) biomarker trial reached its primary endpoint, positioning iPPS as a potentially disease-modifying drug. In our opinion, the initiation of the confirmatory Phase III trial (PARA_OA_003) and six-month follow-up results from the PARA_OA_008 trial represent major catalysts expected in CY23. At end-December 2022, the company had A$83.9m cash, supported by an August 2022 capital raise of A$66.0m.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 8.9 (51.5) (34.3) (16.74) N/A N/A
2022A 0.1 (55.7) (39.2) (16.87) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Further insights


Healthcare Week 2023

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free